Stress States in Pancreatic Cancer

Evidence

This preclinical study examined tumor-intrinsic determinants of response to chimeric antigen receptor (CAR) T-cell therapy in pancreatic ductal adenocarcinoma (PDAC). Investigators integrated modular in vivo CRISPR-Cas9 screening, single-cell genomics, in vitro cytotoxicity assays, and immunocompetent orthotopic models. The core experimental platform was a KPC tumor-derived murine PDAC cell line engineered to stably express luciferase, Cas9, and human CD19. In cytotoxicity experiments, human CD19-targeted or control anti-epidermal growth factor receptor variant III CAR T cells were cocultured with human CD19-positive PDAC cells across varying effector-to-target ratios for 24 hours; conditions were analyzed in triplicate. The study therefore tested tumor-cell genetic and cell-state features within engineered murine tumor and CAR T-cell systems rather than outcomes in people with PDAC. pmid:42826199

In the orthotopic human CD19-positive PDAC model, mice received PDAC cells and then human CD19-targeted CAR T cells, control CAR T cells, or no CAR T cells. There were eight mice per group. The reported tumor comparison showed significant tumor reduction on day 10 with human CD19 CAR T-cell treatment, assessed by Mann-Whitney testing (P = 0.0059). A Kaplan-Meier comparison of mice bearing human CD19-positive PDAC tumors that were untreated or treated with human CD19-targeted or control CAR T cells reported a Mantel-Cox P value of 0.0004. These reported comparisons establish activity in this orthotopic experimental setting, while the supplied result does not provide an effect estimate or confidence interval for either endpoint. pmid:42826199

The investigators also used a mixed-tumor orthotopic model containing equal components of human CD19-positive, green fluorescent protein-positive PDAC cells and CD19-negative, E2-Crimson-positive PDAC cells. Five mice per group received human CD19-targeted or control CAR T cells and underwent flow-cytometric analysis on day 10 for the two labeled tumor-cell populations. CD19-negative PDAC tumor cells enriched after human CD19 CAR T-cell treatment. Within this antigen-defined mixed model, the pattern is consistent with selective pressure against the human CD19-positive component under antigen-specific CAR T-cell exposure; it is not a measure of clinical tumor heterogeneity or a patient outcome. pmid:42826199

CRISPR-Cas9 screening identified disruption of stress-regulatory genes, particularly Keap1 and Slc33a1, as sensitizing PDAC tumors to CAR T-cell killing in vivo. The study then focused on the Keap1/Nrf2 axis. A previously described Nrf2 8xARE-green fluorescent protein reporter was transduced into wild-type PDAC cells, with green fluorescent protein expression used as a readout of Nrf2 transcriptional activity. Treatment with tert-butylhydroquinone produced robust, dose-dependent green fluorescent protein induction in vitro, validating reporter responsiveness in the tested PDAC-cell system. This assay result characterizes transcriptional reporter behavior after a laboratory activator; it does not measure a therapeutic response in patients. pmid:42826199

For in vivo validation, the authors orthotopically transplanted human CD19-positive PDAC cells carrying either a control Olfr402 perturbation or a previously generated Keap1 knockout into C57BL/6 mice. Mice with Keap1-knockout PDAC tumors that received human CD19-targeted CAR T cells had a significant survival advantage compared with mice bearing control PDAC tumors treated with the same CAR T cells (P = 0.0086). The article further reports that endogenous engineering of clinically observed Keap1 or Nfe2l2 mutations enhanced tumor susceptibility to CAR T-cell therapy in the studied models, and describes human tumor-derived Keap1 and Nfe2l2 mutations as sensitizing tumors in those systems. pmid:42826199

Analysis — Preclinical tumor-state associations

The experimental sequence links a screening signal to mechanistic and orthotopic follow-up: CRISPR-Cas9 perturbation nominated stress-regulatory genes, the Nrf2 reporter assessed a related transcriptional state in PDAC cells, and Keap1-altered tumors were compared with control tumors under antigen-specific CAR T-cell treatment. This is a coherent preclinical design for identifying tumor-intrinsic correlates of susceptibility, because the tumor genotype and CAR T-cell condition were experimentally specified. The observed pattern is that Keap1/Nrf2-related stress-state perturbation coincided with greater CAR T-cell susceptibility in engineered murine PDAC models. The mixed-tumor experiment additionally showed enrichment of antigen-negative cells after antigen-specific treatment, a result compatible with antigen-defined selection within that model. pmid:42826199

The comparisons do not establish that a Keap1 or Nfe2l2 alteration will identify a clinically responsive PDAC subgroup. The tested tumors were KPC tumor-derived murine cells modified to express human CD19, and the interventions, antigens, tumor microenvironments, and endpoints were those of the reported laboratory and mouse systems. The survival result compares Keap1-knockout and control tumor-bearing mice receiving human CD19 CAR T cells; it does not isolate every potential biological consequence of the engineered tumor state. Statistical significance in these models does not itself establish clinical significance, safety, efficacy, or patient benefit. pmid:42826199

Limitations

The evidence is preclinical and does not establish clinical safety, efficacy, or patient benefit for CAR T-cell therapy in PDAC. The orthotopic experiments used engineered murine PDAC cells in C57BL/6 mice, including expression of human CD19, so their antigen context and model construction delimit interpretation. The in vitro assays likewise used cultured engineered PDAC cells and short-term CAR T-cell coculture, with triplicate conditions, rather than clinical treatment exposure. The supplied results report P values for selected tumor and survival comparisons but do not supply confidence intervals or effect estimates for those endpoints. pmid:42826199

The article also situates the work against limited success of CAR T-cell therapies in PDAC clinical trials and notes that reasons remain poorly understood. It states that efforts to identify tumor-intrinsic resistance mechanisms have been hampered by a lack of faithful preclinical systems amenable to high-throughput genetic screens. Those contextual points underscore both the rationale for the platform and the uncertainty in translating a screen-based vulnerability from engineered mouse models to human disease. The reported mutation experiments concern tumor susceptibility in the studied models, not validated clinical stratification. pmid:42826199